Iktos vs Numerion Labs (2026)
Both design small molecules with AI, and one sells the software while the other develops its own drugs. Iktos, founded in Paris in 2016, sells Makya for generative design with synthetic accessibility built in, Spaya for retrosynthesis, robotic chemistry and engine APIs, alongside discovery collaborations. Numerion Labs, formerly Atomwise, develops small molecules for immune and inflammatory disease on COSMOS, a chemistry foundation model, APEX for enumerating billions of virtual compounds, and EXPO for optimization. As Atomwise it published the AIMS study, with novel hits for 235 of 318 academic targets. Iktos suits a team that wants to run design tools itself; Numerion is a drug developer whose platform works mainly on its own programs.
- Generative design as software, Makya, with synthesis built into generation.
- Retrosynthesis with Spaya, routing to commercially available starting materials.
- Robotic synthesis, purification and testing, and APIs that plug the models into a team's own workflows.
- A prospective published screening record: novel hits for 235 of 318 academic targets in the AIMS study (Scientific Reports, 2024).
- A current platform of COSMOS, APEX and EXPO, aimed at immune and inflammatory disease.
- Enumeration at scale, described in October 2025 research with NVIDIA.
This comparison is published by AI Health Index, an independent research platform that compares healthcare AI vendors objectively. Iktos and Numerion Labs are each graded against the same capability taxonomy, from each vendor's own public materials and the regulatory record, under the AI Health Index verification standard. No vendor pays for placement, and no vendor has reviewed this page. How this evidence is graded
Plain facts
| Fact | Iktos | Numerion Labs |
|---|---|---|
| Primary category | Drug Discovery AI | Drug Discovery AI |
| Founded | 2016 | Not recorded |
| Headquarters | Paris, France | San Francisco, CA |
| Website | iktos.ai | numerionlabs.ai |
Side by Side
Select any grade to read the note behind it.
Each vendor in one paragraph
Written to be quoted whole. Each paragraph opens the AI Health Index profile of the vendor: what the product is, who buys it and what it does.
Iktos is a Paris generative AI and robotics company for small molecule drug discovery, founded in 2016. It sells two AI platforms: Makya, a generative design SaaS trained on millions of reactions that builds synthetic accessibility and a target product profile into generation (Makya 2.0 added a new analysis interface, and new ligand based 3D generative models arrived in January 2026), and Spaya, an AI retrosynthesis platform that finds routes to commercially available starting materials.
Source: AI Health Index, September 2026
Numerion Labs, formerly known as Atomwise, is a San Francisco AI drug discovery company developing small molecules for immune and inflammatory disease, led by chief executive Steve Worland.
Source: AI Health Index, September 2026
Related comparisons
Other published head to head assessments involving these vendors or their closest peers. The full set for this category is on the Drug Discovery AI page.
Both records were reviewed on this site in September 2026. Neither publishes prices. Part of Iktos's published material could not be read for this review, and Numerion's strongest published result predates its rename.
Ask both how a designed molecule that fails synthesis or testing is fed back into the models.